EMA – First treatment recommended for rare immunoglobulin-related autoimmune disease
EMA’s human medicines committee (CHMP) has recommended extending the therapeutic indication of Uplizna (inebilizumab) to include the treatment of adult patients with active immunoglobulin G4-related disease (IgG4-RD).
IgG4-RD is a rare, chronic, autoimmune condition (a disease caused by the body’s own defence system attacking normal tissue) that can cause fibrosis (tissue scarring) and inflammations in one or multiple organs. Patients with IgG4-RD suffer from new or worsening signs and symptoms in one or more organs. The consequences of inflammation manifest gradually or acutely and can lead to irreversible organ damage and dysfunction. IgG4-RD normally affects people between the ages of 40 and 60. […]
Uplizna contains inebilizumab, a monoclonal antibody (a type of protein) that attaches to immune cells called B cells and destroys them. Uplizna is already approved to treat patients with neuromyelitis optica spectrum disorders (NMOSD).
More information on the EMA Website.
OpenEdition vous propose de citer ce billet de la manière suivante :
vroby (22 novembre 2025). EMA – First treatment recommended for rare immunoglobulin-related autoimmune disease. ELSIBI. Consulté le 19 janvier 2026 à l’adresse https://doi.org/10.58079/156rn





